Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.
A case report of a ciprofloxacin and simvastatin interaction is presented. The addition of ciprofloxacin to chronic simvastatin therapy led to the development of rhabdomyolysis. As ciprofloxacin is a weak inhibitor of CYP3A4, it is very likely that other mechanisms involving the ATP-binding cassette drug efflux transporter family played a role in this drug interaction.
Sawant
R D
RD
The Queen Elizabeth Hospital, Department of Medicine, Kings Lynn, UK. drrahulsawant@hotmail.com
D018528:ATP-Binding Cassette Transporters / Q000187:drug effects / Q000378:metabolism; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology; D002939:Ciprofloxacin / Q000009:adverse effects* / Q000494:pharmacology; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced*; D019821:Simvastatin / Q000009:adverse effects*
D018528:ATP-Binding Cassette Transporters; D000890:Anti-Infective Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D000960:Hypolipidemic Agents; D002939:Ciprofloxacin; D019821:Simvastatin; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human